<DOC>
	<DOC>NCT00359112</DOC>
	<brief_summary>This study compares the effects of Avandamet (rosiglitazone maleate/metformin) treatment and metformin plus sulphonylurea treatment in overweight people with type 2 diabetes.</brief_summary>
	<brief_title>AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criteria: Body mass index &gt; or = to 25 kg/m2. HbA1c &gt; or =7% and &lt; or =10% at screening. FPG &gt; or = 7.0mmol/L (126mg/dL) at visit 2. Receiving at least 0.85g of metformin at constant dose(s) for at least 8 weeks prior to visit 1a. Female subjects must be postmenopausal or using effective contraceptive measures. Exclusion criteria: Use of any other oral antidiabetic drug other than metformin within 12 weeks prior to screening. Subjects with clinically significant ongoing oedema requiring pharmacological treatment or with a history of oedema requiring pharmacological treatment. Subjects with a history of severe hypoglycaemia. Renal disease or renal dysfunction. Presence of clinically significant hepatic disease. Presence of unstable or severe angina or known NYHA grade IIV congestive heart failure. Subjects who have had a previous myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft or cerebrovascular accident within 3 months prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>overweight</keyword>
	<keyword>AVANDAMET</keyword>
	<keyword>metformin</keyword>
	<keyword>sulphonylurea</keyword>
</DOC>